DT-216P2's Phase 1/2 mFARS and frataxin biomarker data in FA sets up a registrational bet contingent on FDA accepting a small-molecule epigenetic approach as approvable

Bull

A positive outcome is the company announcing an agreed-upon registrational trial design with FDA — ideally under a Special Protocol Assessment or Breakthrough Therapy Designation guidance — that accepts mFARS as a primary endpoint or a frataxin biomarker as a surrogate, with a feasible enrollment timeline and sample size. This would confirm that FDA views the epigenetic small-molecule approach as approvable in principle and that the Phase 1/2 data (6.4-point mFARS improvement, statistically significant frataxin protein increases) are sufficient to anchor the pivotal package, materially de-risking the program and likely catalyzing a significant re-rating.

Bear

The most likely failure mode is FDA declining to accept mFARS as a primary endpoint for accelerated approval and requiring a longer, larger outcomes trial with functional milestones that the current data package cannot support, effectively resetting the timeline by several years. A second risk is that FDA flags the transient ALT elevations as a hepatotoxicity signal requiring additional safety data or a modified dosing regimen before a registrational trial can begin, or that the agency requests 12-week MAD data before engaging on trial design, leaving the registrational path undefined well beyond Q4 2026.